Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) announced better-than-expected revenue in Q4 CY2025, with sales up 27.8% year on year to $1.51 billion. Its non-GAAP profit of $1.80 per share was 6.1% below analysts’ consensus estimates.
Is now the time to buy INCY? Find out in our full research report (it’s free for active Edge members).
Incyte (INCY) Q4 CY2025 Highlights:
- Revenue: $1.51 billion vs analyst estimates of $1.35 billion (27.8% year-on-year growth, 11.4% beat)
- Adjusted EPS: $1.80 vs analyst expectations of $1.92 (6.1% miss)
- Adjusted EBITDA: $359.8 million vs analyst estimates of $488.9 million (23.9% margin, 26.4% miss)
- Operating Margin: 22.3%, down from 25.6% in the same quarter last year
- Market Capitalization: $19.64 billion
StockStory’s Take
Incyte’s fourth quarter was met with a negative market reaction, despite the company delivering revenue growth above Wall Street expectations. Management attributed this performance to strong commercial execution across its core products, notably Jakafi and Opsalura, as well as significant progress in the late-stage development pipeline. CEO William Meury highlighted that growth was broad-based, with almost every major product contributing, and commercial milestones were achieved across both established and newly launched therapies. However, higher research and development (R&D) spending and increased operating expenses weighed on margins, partially offsetting the top-line gains.
Looking forward, Incyte’s guidance is driven by anticipated launches in late 2026 and early 2027, ongoing investments in late-stage clinical trials, and the potential for key regulatory approvals. Management believes strong volume growth in core franchises—especially in dermatology and hematology-oncology—will underpin future expansion. Meury noted, “We have much greater visibility into the potential growth profile of the company now than we did at the start of 2025,” and outlined a strategy focused on advancing pivotal trials and maintaining financial discipline while preparing for multiple launches. The company also flagged the importance of expanding formulary access for new indications and capturing growth from both existing and pipeline assets.
Key Insights from Management’s Remarks
Management attributed the quarter’s results to robust product sales, particularly from Jakafi, Opsalura, and hematology-oncology therapies, alongside a significant ramp-up in R&D investment to support a maturing pipeline.
- Jakafi sales momentum: Jakafi continued to be a key revenue driver, with prescription growth across all approved indications. Management highlighted ongoing market penetration in polycythemia vera (PV), where the drug maintains a 30% penetration rate, leaving substantial room for further growth.
- Opsalura expansion: Opsalura saw strong uptake in atopic dermatitis (AD) and vitiligo, with pediatric launch momentum in the United States and early international traction. The segment benefited from increasing clinician and patient preference for nonsteroidal options, as well as successful formulary negotiations.
- Hematology and oncology growth: Products like Niktymbo and Manjoovi contributed meaningfully to sales, with Manjoovi’s expansion into new indications and strong clinical trial data in diffuse large B-cell lymphoma (DLBCL) supporting broader adoption. Management indicated these products are positioned to address unmet needs across multiple cancer subtypes.
- Pipeline advancement: The company advanced several assets from early to late-stage development, including pivotal trials in myeloproliferative neoplasms (MPNs), pancreatic cancer, and hidradenitis suppurativa (HS). Regulatory submissions for key candidates such as Jakafi XR and povastatinib were completed on schedule.
- Investment in R&D and commercialization: Operating expenses increased as Incyte invested in late-stage pipeline assets, clinical trial execution, and launch preparation for upcoming therapies. Management indicated this was a deliberate strategy to support future growth, even as it temporarily pressured operating margins.
Drivers of Future Performance
Management expects near-term performance to be shaped by the pace of new product launches, continued uptake in core indications, and disciplined allocation of R&D resources.
- Upcoming product launches: Late 2026 and early 2027 are expected to bring multiple new launches, most notably Jakafi XR, Opsalura in new indications, and povastatinib for HS. Management believes these introductions will diversify revenue streams and offset future patent expirations.
- Volume-driven core business growth: The company anticipates double-digit volume increases for key products, especially in dermatology and hematology-oncology, with international markets providing incremental growth. Expansion into untreated patient segments and additional indications is projected to sustain a high growth trajectory.
- Margin and expense discipline: While R&D and launch-related expenses are set to rise as pipeline assets mature, management aims to maintain stable cost of goods and flat selling, general, and administrative (SG&A) spend, reallocating resources to support launches without broadly increasing overhead.
Catalysts in Upcoming Quarters
In the coming quarters, our analysts will be closely watching (1) the pace of regulatory filings and upcoming pivotal data readouts across Incyte’s late-stage pipeline, (2) commercial execution and market adoption of new and existing indications for core products like Jakafi and Opsalura, and (3) progress on formulary access and pricing in both U.S. and international markets. The ability to manage R&D investment while supporting multiple product launches will also be a key indicator of execution.
Incyte currently trades at $99.97, down from $109.71 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
Our Favorite Stocks Right Now
The market’s up big this year - but there’s a catch. Just 4 stocks account for half the S&P 500’s entire gain. That kind of concentration makes investors nervous, and for good reason. While everyone piles into the same crowded names, smart investors are hunting quality where no one’s looking - and paying a fraction of the price. Check out the high-quality names we’ve flagged in our Top 6 Stocks for this week. This is a curated list of our High Quality stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025).
Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+782% five-year return). Find your next big winner with StockStory today.